TABLE 1.
Fibroblast quantity, % birefringent collagen, and % elastin for AlloDerm, OrACELL and control groups at 7 and 21 days (mean ± SD)
| Outcome measure | Time point | AlloDerm | OrACELL | Control | p value |
|---|---|---|---|---|---|
| Fibroblast (# cells) | 7 days | 34.03 ± 11.49 | 45.83 ± 19.56 c | 34.90 ± 9.96 | .0495 a |
| 21 days | 38.28 ± 8.87 | 44.50 ± 7.06 c | 36.07 ± 4.84 | .0494 a | |
| BRC (%) | 7 days | 44.55 ± 27.93 | 53.96 ± 23.37 | 41.42 ± 14.34 | .634 |
| 21 days | 55.71 ± 19.75 | 52.05 ± 21.94 | 29.53 ± 22.50 | .121 | |
| Elastin (%) | 7 days | 16.85 ± 6.77 b , c | 11.12 ± 3.41 | 6.71 ± 2.68 | .0036 a |
| 21 days | 7.70 ± 2.63 | 8.09 ± 3.38 | 6.99 ± 2.21 | .831 |
Abbreviation: BRC, birefringent collagen.
a
Indicates significant differences between groups at the indicated time point, where p‐value <.05.
b
Indicates a significant difference compared to control group.
c
Indicates a trend of difference between test groups from post‐hoc Tukey's HSD test where p‐value <.0167.